Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
08/2003
08/13/2003CN1435205A Medicine for treating rheumatoid arthritis and tetanic rachitis
08/13/2003CN1435204A Medicine for treating protrusion of intervertebral disk and hyperplastic spondylitis
08/13/2003CN1435198A Specific Meng medicine pill specially adapted for treating rheumatism
08/13/2003CN1435195A Chinese medicine preparation for treating rheumatoid arthritis and preparing method thereof
08/13/2003CN1435194A Chinese medicine preparation for treating ÔÇ£rheumatic four diseasesÔÇØ and preparing method thereof
08/13/2003CN1435192A ÔÇ£JianzhoukangÔÇØ medicine for medicinal pillow for treating periomethritis and preparing method thereof
08/13/2003CN1435190A Meridians-activating pain-alleviating plaster for treating pains of neck, shoulder, waist and leg
08/13/2003CN1435174A Externally used urotropin nebula and preparing method thereof
08/13/2003CN1117744C 1-(1,2-disubstd. piperidinyl)-4-substd. piperazine derivs.
08/13/2003CN1117583C Medicine for treating lumbago
08/13/2003CN1117580C Ointment for treating bone fracture and injury
08/13/2003CN1117567C Paroxetine controlled release compositions
08/13/2003CN1117563C Analgesic composition for cancer in digestive system
08/12/2003US6605742 Rheumatic diseases; antiarthritic agents; antitumor agents
08/12/2003US6605722 Tyrosine derivatives with anti-leukotrienen activity
08/12/2003US6605702 Protein for use in the treatment of inflammatory defects and asthma
08/12/2003US6605642 Inhibitors of formation of advanced glycation endproducts (AGES)
08/12/2003US6605637 Lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
08/12/2003US6605634 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
08/12/2003US6605633 Such as 5-Bromo-2-phenyl-1H-indole-3-butanoic acid
08/12/2003US6605629 Oxazole derivatives; low toxicity
08/12/2003US6605623 Prevention of asthma and other allergic diseases
08/12/2003US6605616 Autoimmune diseases; inflammation
08/12/2003US6605613 Polyene macrolide antibiotic, especially a rapamycin, and an antioxidant, especially 2,6-di-t-butyl-4-methylphenol; 40-O-(2-hydroxy)ethyl-rapamycin in crystalline form.
08/12/2003US6605610 Aryl fused azapolycyclic compounds
08/12/2003US6605604 Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them
08/12/2003US6605592 Protein HOFNF53
08/12/2003CA2212836C Substituted isoxazoles for the treatment of inflammation
08/08/2003WO2002060922A2 Epoxyvibsanin b
08/08/2003CA2458220A1 Epoxyvibsanin b
08/07/2003WO2003065046A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
08/07/2003WO2003064685A2 Genetic polymorphisms in the preprotachykinin gene
08/07/2003WO2003064638A2 Elongase gene and method for producing polyunsaturated fatty acids
08/07/2003WO2003064629A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003WO2003064626A2 Double-stranded oligonucleotides
08/07/2003WO2003064625A2 Oligonucleotide compositions with enhanced efficiency
08/07/2003WO2003064622A2 Aggrecanase molecules
08/07/2003WO2003064596A2 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003WO2003064472A2 Treatment of ms with goat serum
08/07/2003WO2003064447A2 Immune-modulating peptide
08/07/2003WO2003064443A2 New corticosteroids
08/07/2003WO2003064441A2 Oligonucleotides comprising alternating segments and uses thereof
08/07/2003WO2003064440A1 Compounds that inhibit factor xa activity
08/07/2003WO2003064397A1 Indazole compounds useful as protein kinase inhibitors
08/07/2003WO2003064387A2 Substituted indoles as alpha-1 agonists
08/07/2003WO2003064383A2 Phosphorus-containing compounds & uses thereof
08/07/2003WO2003063911A1 Decoy-containing pharmaceutical compositions and method of using the same
08/07/2003WO2003063908A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
08/07/2003WO2003063906A1 Drugs for treating inflammatory diseases
08/07/2003WO2003063905A1 Preventives or remedies for immunological diseases
08/07/2003WO2003063898A2 Method of treating pain with botulinum toxin
08/07/2003WO2003063875A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003WO2003063859A1 Suppression of cartilage degradation via the estrogen receptor
08/07/2003WO2003063844A2 Treatment of rheumatoid arthritis using imatinie
08/07/2003WO2003063834A1 Multi-stage oral drug controlled-release system
08/07/2003WO2003063806A1 Topical anti-inflammatory compositions and methods of reducing inflammation
08/07/2003WO2003063800A2 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/07/2003WO2003063799A2 Compositions and methods for systemic inhibition of cartilage degradation
08/07/2003WO2003063796A2 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003WO2003063794A2 2,4-pyrimidinediamine compounds and their uses
08/07/2003WO2003063758A2 Bicyclic cb2 cannabinoid receptor ligands
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2003028662A3 A method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
08/07/2003WO2002068476A3 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002046386A3 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
08/07/2003WO2002004015A9 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149385 Ultraviolet-schielding adhesive preparation
08/07/2003US20030149383 Patch containing anti-inflammatory agent
08/07/2003US20030149266 Administering to a patient (a warm blooded animal, such as man) an effective amount of a pyrimidine derivative for treating cancer, cell proliferation, and inhibition of focal adhesion kinase effect
08/07/2003US20030149249 Process for isolation of osteopontin from milk
08/07/2003US20030149247 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
08/07/2003US20030149242 Novel polypeptide
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149108 Linked biaryl compounds
08/07/2003US20030149094 Compositions comprising ether compounds and pharmaceutical uses therefor
08/07/2003US20030149091 For therapy of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder
08/07/2003US20030149083 For therapy of inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic erythematodes, multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis
08/07/2003US20030149081 For therapy and prophylaxis of asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, atherosclerosis
08/07/2003US20030149068 Use of chrysanthone A for the preparation of a medicament with antiangiogenic activity
08/07/2003US20030149066 Administering nalbuphine or a prodrug of nalbuphine, and an opioid antagonist selected from the group consisting of naloxone, naltrexone, nalmefene, pharmaceutically acceptable salts thereof or prodrugs
08/07/2003US20030149062 Therapy of inflammatory diseases of the airways or intestines which by administering substances selected from quinazoline derivatives, 4-((3-chloro-4-fluorophenyl)amino)-6-((4-dimethylamino-cyclohexyl)amino) -pyrimido(5,4-d)pyrimidine
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149057 Anti-cancer compounds
08/07/2003US20030149051 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149039 For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient
08/07/2003US20030149037 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc.
08/07/2003US20030149034 Indazoles substituted with1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
08/07/2003US20030149031 For therapy of inflammation
08/07/2003US20030149023 Novel compounds with analgesic effect
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149006 New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148983 Polynucleotide therapy
08/07/2003US20030148963 Use of etoposide at the manufacture of pharmaceutical formulations intended for the treatment of inflammations in mammals, including humans
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
1 ... 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 ... 1272